Dr. Conn Lives on: Insights Into Screening and Genetics of Primary Aldosteronism

D, Stein; Yee, Jerry

doi:10.1053/j.ackd.2019.03.018

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Even among academic centers, <10% of patients with resistant hypertension are screened for primary aldosteronism, and early diagnosis remains uncommon. 41,42 Beyond patients with true resistant hypertension, it is also reasonable to evaluate secondary causes in young hypertensive individuals, patients with accelerated or abrupt-onset hypertension, and in patients with signs, symptoms or laboratory findings indicating a discrete etiology. The presence of hypertension-mediated organ damage or severe comorbidities will intensify the need for BP lowering.…”

Section: Lack Of Progress In Hypertension Controlmentioning

confidence: 99%

See 1 more Smart Citation

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Kandzari

Townsend

Bakris

et al. 2021

Cathet Cardio Intervent

View full text Add to dashboard Cite

Despite the availability of efficacious pharmacological treatments, hypertension remains the leading global cause of death and disability, 1 and rates of blood pressure (BP) control are stagnant, if not modestly declining. In the United States alone, for example, more than one-half of individuals with hypertension do not meet societal or guideline-directed BP goals, representing more than 29 million people. 2,3 Although reasons are multifactorial, patient non-adherence, physician inertia, as well as barriers such as lack of social support, depression and complex polypharmacy regimens are major contributors to lack of BP goal achievement.Interventional strategies, such as catheter-based renal denervation (RDN) using radiofrequency energy, ultrasound, or perivascular injection of neurotoxic agents, are gaining increasing attention. The rationale for RDN is to interrupt the activity of afferent and efferent

show abstract

Section: Lack Of Progress In Hypertension Controlmentioning

confidence: 99%

“…The prevalence of primary aldosteronism in patients with resistant hypertension is above 20% but largely unrecognized 40 . Even among academic centers, <10% of patients with resistant hypertension are screened for primary aldosteronism, and early diagnosis remains uncommon 41,42 …”

Section: Multidisciplinary Evaluation and Treatment Decision‐makingmentioning

confidence: 99%

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Kandzari

Townsend

Bakris

et al. 2021

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Most of the mutations identified activate intracellular pathways leading to increased intracellular calcium and trigger increased aldosterone production. Identifying these gene mutations can have potential implications for diagnosis and treatment but to date remain a research tool that is not yet clinically applied [25 ▪▪ ,26 ▪ ].…”

Section: Primary Aldosteronismmentioning

confidence: 99%

Chronic kidney disease in adrenal disorders

Salman

Cohen²

2021

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review This review will focus on hypertension due to underlying adrenal disorders in chronic kidney disease (CKD). Diagnosis of adrenal hypertension and particularly primary aldosteronism (PA) in CKD is frequently not pursued. We outline limitations that advanced kidney disease poses on the diagnostic work up of these disorders and provide a framework for approaching CKD patients suspected of having an adrenal disorder. Recognition of these disorders is important as they are often underdiagnosed which leads to poorer outcomes. Recent findings Adrenal disease associated with hypertension in CKD is most commonly due to PA whereas pheochromocytoma and Cushing's disease are important but less common. Diagnosis of these diseases is important as their identification leads to better blood pressure control and can possibly mitigate the risk of progression of CKD. Work up and treatment of PA has been shown to be safe and is associated with less antihypertensive medication requirement for the associated hypertension and slower progression of CKD. Summary This chapter summarizes the importance of recognizing adrenal hypertension in CKD and reinforces the need for physicians to pursue these diagnoses in CKD patients as this is safe and improves both BP control and delays progression of CKD.

show abstract

“…Існування різновидів родинного гіперальдостеронізму з відомими генетичними мутаціями дало унікальну можливість вивчити незалежно від артеріального тиску ефекти надлишку альдостерону. Дослідження членів цих родин дозволило виявити осіб з підтвердженим біохімічним способом ПГА до початку АГ, а отже, й оцінити ефекти надлишку альдостерону незалежно від рівня артеріального тиску [29,30].…”

Section: рисунок 3 механізми за допомогою яких надлишок альдостерону спричиняє розвиток фібриляції передсердь і серцевої недостатностіunclassified

Первичный Гиперальдостеронизм. Механизмы И Последствия Патологического Воздействия На Организм (Обзор Литературы)

Shidlovsky¹,

Shidlovsky²,

Kravtsiv³

2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Работа построена на анализе данных мировой литературы, посвященной первичному гиперальдостеронизму. Приведены данные о механизмах патологического воздействия на системы организма избыточной автономной секреции альдостерона. Раскрыты пути влияния избытка альдостерона на сердечно-сосудистую и нервную системы, почки, качество и продолжительность жизни. Показано, что альдостерон активирует специфические внутриклеточные геномные и негеномные пути влияния на сердечно-сосудистую систему и индуцирует развитие кардиофиброза, фибрилляции предсердий и сердечной недостаточности. Обращено внимание на то, что гиперальдостеронизм является причиной развития метаболического синдрома, ухудшения качества и продолжительности жизни.

show abstract

Dr. Conn Lives on: Insights Into Screening and Genetics of Primary Aldosteronism

Cited by 4 publications

References 18 publications

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Chronic kidney disease in adrenal disorders

Первичный Гиперальдостеронизм. Механизмы И Последствия Патологического Воздействия На Организм (Обзор Литературы)

Contact Info

Product

Resources

About